News

2025.04.01

Press Release

Announcement of Strengthening Management Structure at iXgene

2024.12.25

Press Release

iXgene and C4U Partner on Collaborative Research for CRISPR-Cas3 Genome Editing Technology

2024.09.02

Announcement

We moved our office.

2024.02.09

Announcement

iXgene Inc. signs License Agreement with Keio University Educational Corporation for Commercialization of Suicide Gene Transfer iPS Cell Patents

2023.10.10

Press Release

Announcement of a three-way joint research agreement between iXgene, Keio University School of Medicine, and Sumitomo Pharma for the practical application of a treatment for malignant brain tumors using genome-edited iPS cells.

2023.01.05

Press Release

Keio Innovation Initiative/University of Tokyo Collaborative Creation Platform Development/MSF Capital Partners/Green Core to carry out third-party allotment capital increase totaling 600 million yen